Epicondylitis of the Elbow
Conditions
Keywords
Epicondylitis
Brief summary
The purpose of the this study is to evaluate the sfaety and efficacy of Synera(R)for patients with lateral and medial epicondylitis and compare it to Naproxen sodius.
Detailed description
The objective of this single center is to evaluate the safety and efficacy of Synera ® in lateral and medial epicondylitis . This is an open-label, comaparative study study where the subjects will be randomized to one of the following groups: 1. Synera patch ®: A single patch applied for 4 hours twice daily approximatey 12 hrs apart to the medial or lateral side of the index elbow 2. Synera patch ®: A single patch applied for 12 hours/day to the medial or lateral side of the index elbow 3. Naproxen Sodium: 500mg bid
Interventions
DRUGNaproxen
Naproxen 500mg BID for the first 2 weeks
DRUGSynera patch twice daily
1 synera patch to cover the treatment area applied for 4 hours, twice daily for the first 2 weeks
DRUGSynera patch for 12hrs/day
1 synera patch to cover the treatment area applied for 12 hours, daily for the first 2 weeks
DRUGSynera
Topical appication of single patch to elbow for 12hrs/day
Sponsors
International Clinical Research Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Individuals with clinical evidence of lateral or medial epicondylitis of the elbow. * Age 18 or higher * Minimum of 4 on Question 5 of BPI
Exclusion criteria
* Peripheral neuropathy of any origin in the index limb * Cubital tunnel syndrome in patients with medial epicondylitis * Cortisone injection in the last 4 weeks into the index limb * Surgical intervention in the past for the epicondiitis * Participants in any other clinical trial in the last 30 days * Known allergy to lidocaine, tetracaine, NSAIDs or PABA * Uncontrolled pain in the upper extremity or neck that may interfere with evaluation of study drug's response as deemed by the investigator * Patient who is deemed to be medically unstable by the principal investigator including but not limited to Liver disease or Cardiac arrhythmias * Patients who are pregnant, lactating or breast feeding * Vaccination within the last weeks or planning on any vaccinations during the study or for 4 weeks after the study completion.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline recorded at 2 week visit for the question #5 of Brief Pain Inventory (BPI )Scale ® recorded before going to sleep daily | Day 1 and Day 14 | Brief Pain Inventory (BPI )Scale ® recorded before going to sleep daily by the subject and the answer for question 5 is the basis for primary end poit |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pain quality assessment scale | Every visit from the entry | It is a vlaidated measure to assess the qulaity of scale |
Countries
United States
Outcome results
None listed